A nationwide survey of deep fungal infections and fungal prophylaxis after hematopoietic stem cell transplantation in Japan

被引：22

作者：

Imataki, O

Kami, M

Kim, SW

Gotoh, M

Komaba, S

Kasai, M

Hashino, S

Naito, K

Masuda, M

Anan, K

Teshima, H

Togitani, K

Inoue, T

Nishimura, M

Adachi, Y

Fukuhara, T

Yamashita, T

Uike, N

Kobayashi, Y

Hamaguchi, M

Higuchi, M

Kawakami, K

Takaue, Y

机构：

[1] Natl Canc Ctr, Hematopoiet Stem Cell Transplantat Unit, Chuo Ku, Tokyo 1040045, Japan

[2] Teikyo Univ, Sch Med, Div Hematol, Tokyo 173, Japan

[3] Sapporo Hokuyu Hosp, Dept Internal Med, Sapporo, Hokkaido, Japan

[4] Hokkaido Univ, Sch Med, Dept Hematol & Gastroenterol, Sapporo, Hokkaido 060, Japan

[5] Hamamatsu Univ Sch Med, Dept Med 3, Shizuoka, Japan

[6] Tokyo Womens Med Sch, Div Hematol, Tokyo, Japan

[7] Tohoku Univ, Inst Dev Aging & Canc, Sendai, Miyagi 980, Japan

[8] Osaka City Gen Hosp, Osaka, Japan

[9] Kochi Med Sch, Dept Internal Med, Kochi, Japan

[10] Shiga Univ Med Sci, Dept Hematol, Shiga, Japan

[11] Chiba Univ, Sch Med, Dept Internal Med 2, Chiba 280, Japan

[12] Shakaihoken Kobe Cent Hosp, Kobe, Hyogo, Japan

[13] Asahikawa City Hosp, Dept Internal Med, Asahikawa, Hokkaido, Japan

[14] Natl Def Med Coll, Dept Internal Med 3, Saitama, Japan

[15] Kyushu Natl Canc Ctr, Dept Hematol, Fukuoka, Japan

[16] Kyoto Prefectural Univ Med, Dept Internal Med, Div Hematol & Oncol, Kyoto, Japan

[17] Nagoya Natl Hosp Clin & Res Ctr, Dept Hematol, Aichi, Japan

[18] Hamanomachi Gen Hosp, Dept Hematol, Fukuoka, Japan

[19] Suzuka Gen Hosp, Div Hematol, Suzuka, Mie, Japan

来源：

BONE MARROW TRANSPLANTATION | 2004年 / 33卷 / 12期

关键词：

hematopoietic stem cell transplantation; (HSCT); fungal infection; antifungal prophylaxis; reduced-intensity; stem cell transplantation (RIST);

D O I：

10.1038/sj.bmt.1704526

中图分类号：

Q6 [生物物理学];

学科分类号：

071011 ;

摘要：

We conducted a nationwide survey to de. ne incidence of deep fungal infections and fungal prophylaxis practices after HSCT. In all, 63 institutions responded. Total number of in-patient transplantations was 935: 367 autologous, 414 allogeneic myeloablative, and 154 allogeneic reduced-intensity (RIST) (n = 154). N umber of patients who were cared for in a clean room at transplant was 261 (71%) in autologous, 409 (99%) in conventional and 93 (66%) in RIST, respectively. All patients received prophylactic antifungal agents; 89%. uconazole. Number of patients who received the dosage recommended in the CDC guidelines (400 mg/day) was 135 (42%) in conventional transplant and 34 (30%) in RIST (P = 0.037). Number of patients who received. uconazole until engraftment and beyond day 75 in conventional transplant vs RIST was, respectively, 324 ( 100%) vs 109 (97%), and 39 (12%) vs 18 (16%), with no significant difference between the two groups. A total of 37 patients (4.0%) were diagnosed with deep fungal infections; autologous transplantation (0.03%), conventional transplantation (6.0%) and RIST (7.1%). Wide variations in antifungal prophylaxis practice according to the type of transplant and the institutions, and deep fungal infection remain significant problems in RIST.

引用

页码：1173 / 1179

页数：7

共 44 条

[11] Developing a pediatric outpatient transplantation program. The Children's Memorial Hospital experience [J].

Gonzalez-Ryan, L ;

Haut, PR ;

Coyne, K ;

Van Syckle, K ;

Duerst, R ;

Haro, D ;

Kletzel, M .

FRONTIERS IN BIOSCIENCE-LANDMARK, 2001, 6 :G1-G5

[12] A CONTROLLED TRIAL OF FLUCONAZOLE TO PREVENT FUNGAL-INFECTIONS IN PATIENTS UNDERGOING BONE-MARROW TRANSPLANTATION [J].

GOODMAN, JL ;

WINSTON, DJ ;

GREENFIELD, RA ;

CHANDRASEKAR, PH ;

FOX, B ;

KAIZER, H ;

SHADDUCK, RK ;

SHEA, TC ;

STIFF, P ;

FRIEDMAN, DJ ;

POWDERLY, WG ;

SILBER, JL ;

HOROWITZ, H ;

LICHTIN, A ;

WOLFF, SN ;

MANGAN, KF ;

SILVER, SM ;

WEISDORF, D ;

HO, WG ;

GILBERT, G ;

BUELL, D .

NEW ENGLAND JOURNAL OF MEDICINE, 1992, 326 (13) :845-851

[13] High rate of invasive fungal infections following nonmyeloablative allogeneic transplantation [J].

Hagen, EA ;

Stern, H ;

Porter, D ;

Duffy, K ;

Foley, K ;

Luger, S ;

Schuster, SJ ;

Stadtmauer, EA ;

Schuster, MG .

CLINICAL INFECTIOUS DISEASES, 2003, 36 (01) :9-15

[14] Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis [J].

Herbrecht, R ;

Denning, DW ;

Patterson, TF ;

Bennett, JE ;

Greene, RE ;

Oestmann, JW ;

Kern, WV ;

Marr, KA ;

Ribaud, P ;

Lortholary, O ;

Sylvester, R ;

Rubin, RH ;

Wingard, JR ;

Stark, P ;

Durand, C ;

Caillot, D ;

Thiel, E ;

Chandrasekar, PH ;

Hodges, MR ;

Schlamm, HT ;

Troke, PF ;

de Pauw, B .

NEW ENGLAND JOURNAL OF MEDICINE, 2002, 347 (06) :408-415

[15]

Kami M, 2001, AM J HEMATOL, V66, P85, DOI 10.1002/1096-8652(200102)66:2<85::AID-AJH1022>3.0.CO

[16]

2-M

[17] Effect of fluconazole prophylaxis on fungal blood cultures: an autopsy-based study involving 720 patients with haematological malignancy [J].

Kami, M ;

Machida, U ;

Okuzumi, K ;

Matsumura, T ;

Mori, S ;

Hori, A ;

Kashima, T ;

Kanda, Y ;

Takaue, Y ;

Sakamaki, H ;

Hirai, H ;

Yoneyama, A ;

Mutou, Y .

BRITISH JOURNAL OF HAEMATOLOGY, 2002, 117 (01) :40-46

[18]

Kami M, 2000, HAEMATOLOGICA, V85, P745

[19]

Kanda Y, 1998, HEMATOL ONCOL, V16, P33, DOI 10.1002/(SICI)1099-1069(1998030)16:1<33::AID-HON620>3.3.CO

[20]

2-0

← 1 2 3 4 5 →